Literature DB >> 17188882

Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.

Walter Maetzler1, Daniela Berg, Natalie Schalamberidze, Arthur Melms, Klaus Schott, Jakob C Mueller, Lucy Liaw, Thomas Gasser, Cordula Nitsch.   

Abstract

In the pathogenesis of Parkinson's disease (PD), oxidative and nitrosative stress, apoptosis, mitochondrial dysfunction, and excitotoxicity are involved, i.e., processes in which osteopontin (OPN) may also play a role. We have studied in PD patients serum and cerebrospinal fluid (CSF) concentrations of OPN, its immunohistochemical presence in substantia nigra (SN) and tested in OPN-null mice the impact of this protein on MPTP-induced neurodegeneration. PD was accompanied by increased OPN levels in the body fluids. Higher serum levels were associated with more severe motor symptoms. CSF levels were positively associated with concomitant dementia and negatively associated with dopaminergic treatment. In human SN, OPN was expressed in neurons, in their Lewy bodies and in microglia. Loss of tyrosine-hydroxylase-positive cells in the SN and of dopaminergic fibers in the striatum was reduced 3 weeks after MPTP intoxication in OPN-null mice. These data suggest that OPN is involved in PD-associated neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188882     DOI: 10.1016/j.nbd.2006.10.020

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  43 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury.

Authors:  Julie L Chan; Thomas M Reeves; Linda L Phillips
Journal:  Exp Neurol       Date:  2014-08-21       Impact factor: 5.330

3.  Acute intranasal osteopontin treatment in male rats following TBI increases the number of activated microglia but does not alter lesion characteristics.

Authors:  Amandine Jullienne; Mary Hamer; Elizabeth Haddad; Alexander Morita; Peter Gifford; Richard Hartman; William J Pearce; Jiping Tang; John H Zhang; Andre Obenaus
Journal:  J Neurosci Res       Date:  2019-03-20       Impact factor: 4.164

4.  Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice.

Authors:  Walter Maetzler; Daniela Berg; Claudia Funke; Freya Sandmann; Holger Stünitz; Corina Maetzler; Cordula Nitsch
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

5.  Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals.

Authors:  Amanda Brown; Tanzeem Islam; Robert Adams; Sujata Nerle; Masiray Kamara; Caitlin Eger; Karen Marder; Bruce Cohen; Giovanni Schifitto; Justin C McArthur; Ned Sacktor; Carlos A Pardo
Journal:  J Neurovirol       Date:  2011-05-10       Impact factor: 2.643

6.  Osteopontin is not critical for otoconia formation or balance function.

Authors:  Xing Zhao; Sherri M Jones; Wallace B Thoreson; Yunxia Wang Lundberg
Journal:  J Assoc Res Otolaryngol       Date:  2008-05-06

7.  The immunohistochemical expression profile of osteopontin in normal human tissues using two site-specific antibodies reveals a wide distribution of positive cells and extensive expression in the central and peripheral nervous systems.

Authors:  Yasuto Kunii; Shin-ichi Niwa; Yoshiaki Hagiwara; Masahiro Maeda; Tsutomu Seitoh; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2009-09-26       Impact factor: 2.309

8.  Characterization of osteopontin expression and function after status epilepticus.

Authors:  Karin Borges; Marla Gearing; Susan Rittling; Esben S Sorensen; Robert Kotloski; David T Denhardt; Raymond Dingledine
Journal:  Epilepsia       Date:  2008-06-03       Impact factor: 5.864

9.  Osteopontin regulates hindlimb-unloading-induced lymphoid organ atrophy and weight loss by modulating corticosteroid production.

Authors:  Kathryn X Wang; Yufang Shi; David T Denhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-04       Impact factor: 11.205

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.